舒肝解郁胶囊联合阿立哌唑治疗精神分裂症的效果及对氧化应激水平的影响

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (0 KB) HTML (44 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Shugan Jieyu Capsules combined with Aripiprazole in the treatment of schizophrenia and its influence on the levels of oxidative stress.Methods A total of 80 patients diagnosed with schizophrenia and treated in our hospital from January to December 2018 were selected as research objects,and they were divided into the control group and the observation group according to the random principle,40 cases in each group.The control group was treated with Aripiprazole orally,while the patients in the observation group were treated with Shugan Jieyu Capsules combined with Aripiprazole orally.The positive and negative symptom scale (PANSS)scores and the levels of oxidative stress indicators(total superoxide dismutase[T-SOD],glutathione peroxidase[GSH-Px],catalase[CAT])before and after treatment were observed between the two groups.The total effective rate of treatment was compared between the two groups of patients.Results There were no significant differences in the PANSS scores between the two groups before treatment(P>0.05).The PANSS scores of the two groups after 8 weeks of treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).The score of negative symptoms in the observation group was significantly lower than that in the control group after 8 weeks of treatment,and the difference was statistically significant(P<0.05).There was no significant difference in the total effective rate of treatment between the two groups (P>0.05).There were no significant differences in serum levels of T-SOD,GSH-Px and CAT between the two groups before treatment(P>0.05).After treatment,the serum levels of T-SOD and GSH-Px in the two groups were higher than those before treatment,and the CAT level was significantly lower than that before treatment,with statistically significant differences(P<0.05).The serum levels of T-SOD and GSH-Px in the observation group after treatment were higher than those in the control group,and the CAT level was lower than that in the control group,with statistically significant differences (P<0.05).Conclusion Shugan Jieyu Capsules combined with Aripiprazole can effectively improve the clinical symptoms of schizophrenia patients and help to enhance the oxidative stress ability of patients.

Key words： Shugan Jieyu Capsules Aripiprazole Schizophrenia Oxidative stress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Yun
	LU Wei-yu
	CUI Wen-yan
	ZHONG Yu-long
	GUO Yue-ping
	KUANG Ye

Cite this article:

GAO Yun,LU Wei-yu,CUI Wen-yan, et al. Effect of Shugan Jieyu Capsules combined with Aripiprazole in the treatment of schizophrenia and its influence on the levels of oxidative stress[J]. 中国当代医药, 2019, 26(16): 47-50转54.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I16/47

[1]	Charlson FJ，Ferrari AJ，Santomauro DF，et al.Global epidemiology and burden of schizophrenia：findings from the global burden of disease study 2016[J].Schizophr Bull，2018，44（6）：1195-1203.
[2]	赵晶媛，黄光彪，顾小静，等.4种第二代抗精神病药物治疗精神分裂症急性期的临床观察[J].中国药房，2016，27（20）：2790-2794.
[3]	周云飞，刘铁榜.舒肝解郁胶囊临床研究进展[J].中国医药导刊，2017，19（3）：285-286.
[4]	王含彦，郭冬梅，唐珍，等.舒肝解郁胶囊的抗抑郁作用及其机制[J].中成药，2018，40（1）：187-190.
[5]	传娟娟，李燕.贯叶金丝桃（圣约翰草）的国内外研究概况[J].西北药学杂志，2016，31（3）：330-333.
[6]	江君，郭树仁，赵君贤，等.贯叶金丝桃抗菌作用研究综述[J].中国医药生物技术，2010，5（5）：381-384.
[7]	苗纯峰，张雅致，慕存才.抗精神病药合并舒肝解郁胶囊改善精神分裂症患者阴性症状的疗效分析[J].北方药学，2017，14（11）：47.
[8]	Ng F，Berk M，Dean O，et al.Oxidative stress in psychiatric disorders：evidence base and therapeutic implications[J].Int J Neuropsychopharmacol，2008，11（6）：851-876.
[9]	中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版（精神障碍分类）[J].中华精神科杂志，2001，34（3）：184-188.
[10]	杨朝晖，索冠伟.最新国际疾病分类精神分裂症和其他原发性精神障碍精神症状评定进展[J].中国神经精神疾病杂志，2018，44（1）：55-57.
[11]	唐宇凤，施剑，张献文，等.舒肝解郁胶囊与舍曲林治疗心因性头晕的临床对照试验[J].四川精神卫生，2016，29（1）：55-57.
[12]	李刚.舒肝解郁胶囊联合阿立哌唑治疗老年精神分裂症阴性症状的临床研究[J].中国医药科学，2014，4（1）：96-97.
[13]	郑英君，吴超，宁玉萍，等.用药态度对精神分裂症患者治疗依从性和症状影响的1年随访研究[J].中国神经精神疾病杂志，2017，43（7）：385-390.
[15]	陈昊天，周郁秋，孙玉静，等.精神分裂症精神残疾影响因素的研究进展[J].神经疾病与精神卫生，2016，16（3）：333-337.
[16]	史晓蒙，徐西嘉.精神分裂症的药物治疗抵抗[J].临床精神医学杂志，2016，26（3）：206-208.
[17]	吴西志，吴运渠，吴运畴，等.中医药治疗精神分裂症的研究进展[J].中医临床研究，2015，7（31）：147-148.
[18]	蒋永红，王乃信，金卫东，等.中药治疗精神分裂症患者代谢综合征疗效观察[J].中华中医药学刊，2013，31（7）：1593-1594.
[19]	周云飞，刘铁榜.舒肝解郁胶囊临床研究进展[J].中国医药导刊，2017，19（3）：285-286.
[14]	Citrome L.Activating and sedating adverse effects of second-generationantipsychoticsinthetreatmentofschizophrenia and major depressive disorder：absolute risk increase and number needed to harm[J].J Clin Psychopharmacol，2017，37（2）：138-147.
[20]	陈志强，郭俊芳，封敏.舒肝解郁胶囊治疗首发精神分裂症急性期的疗效观察[J].中华中医药学刊，2016，34（3）：728-730.
[21]	李永强，乔兴菊，冯金河.奥氮平合并舒肝解郁胶囊治疗精神分裂症的对照研究[J].中国伤残医学，2013，21（3）：31-33.
[22]	Peralta V，Cuesta MJ，Martinez-Larrea A，et al.Differentiating primary from secondary negative symptoms in schizophrenia：a study of neuroleptic-naive patient sbefore and after treatment[J]Am J Psychiat，2000，158（9）：1461-1466.
[23]	陈科.舒肝解郁胶囊联合舍曲林改善老年精神分裂症阴性症状的效果研究[J].中华全科医学，2016，14（5）：780-781.
[24]	张丽娜，张博，伊琦忠.阿立哌唑和奥氮平治疗精神分裂症的效果、血糖及血脂代谢的比较[J].中国医药导报，2017，14（35）：102-105.
[25]	黄东，刘少文.氧化应激与精神分裂症的研究现况[J].国际精神病学杂志，2018，45（2）：208-210.
[26]	Sarandol A，Sarandol E，Acikgoz HE，et al.First-episode psychosis is associated with oxidative stress：effects of short-term antipsychotic treatment[J].Psychiatry Clin Neurosci，2015，69（11）：699-707.
[27]	晁阳阳，盛卫勇，赵瑾，等.首发精神分裂症外周血氧化应激状态改变[J].中国神经精神疾病杂志，2016，42（8）：449-453.
[28]	董伟，顾卫霞，唐小伟，等.黄连素联合利培酮治疗对精神分裂症患者内分泌激素、氧化应激程度的影响[J].海南医学院学报，2017，23（13）：1870-1873.
[29]	孙文贤，安红梅.中药对神经氧化应激损伤保护作用的机制研究[J].中医学报，2015，30（4）：561-564.
[30]	杨诗婷，王晓倩，廖广辉.金丝桃苷的药理作用机制研究进展[J].中国现代应用药学，2018，35（6）：947-951.